APM:NSD-Aptorum Group Limited (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.64

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.11M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Company Website : http://www.aptorumgroup.com

Address : 17 Hanover Square, London, United Kingdom, W1S 1BN

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.21

52 Week High : 4.56

Short Ratio : 0.78

52 Week Low : 1.16

Shorted Shares : 317,358

200 Day Moving Average : 3.00

Shorted Shares Previous Month : 194,718

50 Day Moving Average : 3.03

Shares Held By Insiders : 37.42%

Short Percentage : 1.00%

Shares Held by Institutions : 1.71%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

 USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD62.47B 16.69 13.11
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

 USD29.28B N/A N/A
GMAB Genmab A/S

N/A

 USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

 USD26.42B 40.63 36.19
RPRX Royalty Pharma plc

N/A

 USD24.49B 33.25 14.59
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD21.44B N/A N/A

ETFs Containing APM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.88% 68% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.88% 68% D+ 49% F
Trailing 12 Months  
Capital Gain -27.07% 36% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.07% 36% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -33.81% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.81% 4% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 39.39% 75% C 46% F
Risk Adjusted Return -85.82% 4% F 2% F
Market Capitalization 0.09B 18% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.25 42% F 61% D-
Price/Book Ratio 2.36 68% D+ 56% F
Price / Cash Flow Ratio -5.92 44% F 66% D
EV/EBITDA 10.68 34% F 67% D+
Management Effectiveness  
Return on Equity 18.57% 95% A 87% B+
Return on Invested Capital -60.95% 39% F 13% F
Return on Assets -36.11% 26% F 8% F
Debt to Equity Ratio 4.80% 64% D 79% C+
Technical Ratios  
Short Ratio 0.78 84% B 77% C+
Short Percent 4.46% 65% D 40% F
Beta -0.21 96% A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.